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Abstract
Infection withMycobacterium tuberculosis (Mtb) is the leading cause of death in human
immunodeficiency virus (HIV)+ individuals, particularly in Sub-Saharan Africa. Management
of this deadly co-infection is a significant global health challenge that is exacerbated by the
lack of efficient vaccines against bothMtb and HIV, as well as the lack of reliable and robust
animal models forMtb/HIV co-infection. Here we describe a tractable and reproducible
mouse model to study the reactivation dynamics of latentMtb infection following the loss of
CD4+ T cells as it occurs in HIV-co-infected individuals. Whereas intradermally (i.d.)
infected C57BL/6 mice containedMtb within the local draining lymph nodes, depletion of
CD4+ cells led to progressive systemic spread of the bacteria and induction of lung pathol-
ogy. To interrogate whether reactivation ofMtb after CD4+ T cell depletion can be reversed,
we employed interleukin (IL)-2/anti-IL-2 complex-mediated cell boost approaches. Although
populations of non-CD4 lymphocytes, such as CD8+ memory T cells, natural killer (NK)
cells and double-negative (DN) T cells significantly expanded after IL-2/anti-IL-2 complex
treatment, progressive development of bacteremia and pathologic lung alterations could
not be prevented. These data suggest that the failure to reverseMtb reactivation is likely
not due to anergy of the expanded cell subsets and rather indicates a limited potential for IL-
2-complex-based therapies in the management ofMtb/HIV co-infection.
Introduction
Infections withMtb, the causative agent of tuberculosis (TB), are the major cause of death in
human immunodeficiency virus (HIV)+ individuals, accounting for approximately 25% of all
HIV-related fatalities [1]. Together, TB and HIV/AIDS account for more than 2 million deaths
per year [1, 2] and HIV+ individuals are 30 times more likely to develop active TB than HIV−
individuals [2]. Both pathogens profoundly impact on the human immune system and the
gradual decline of CD4+ T cells, the hallmark of HIV infection, is believed to be a major con-
tributing factor in the progression to active TB disease and premature death [3]. CD4+ T cells
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are not only prime producers of interferon gamma (IFN-γ), a critical cytokine for TB control,
but also play essential roles in the maturation of the humoral immune response and the struc-
tural integrity ofMtb-containing solid granulomas [4]. Particularly the HIV-induced preferen-
tial destruction of mucosal effector memory CD4+ T cells [5] and CD1-restricted
mycobacterial glycolipid-reactive T cells [6], as well as the imbalance between Th17 and regula-
tory T cell (Treg) populations [7] apparently favourMtb reactivation. Although anti-retroviral
therapy (ART) largely restores CD4+ T cell numbers, the increased risk for reactivation of
latent TB infection (LTBI) is only partially diminished [8]. In order to develop intervention
strategies againstMtb that are also effective in HIV+ individuals, it is therefore useful to identify
CD4-independent mechanisms which contribute to control ofMtb infection.
We have recently described a critical role for non-cognate production of IFN-γ by NK cells,
memory CD8+ T cells and DN T cells in TB [9]. Rapid secretion of IFN-γ by these lymphocyte
populations in TB required the sensing of ESAT-6-mediated cytosolic contact via NLRP3
inflammasomes within CD11c+ cells and the subsequent secretion of bioactive interleukin
(IL)-18. These results not only delineate a mechanistic framework for IFN-γ production by IL-
18 responsive cell types afterMtb infection, but also indicate an inherent capacity of non-CD4
immune cells to contribute to protective immunity. In order to potentially harness non-CD4
immune cell subsets in settings where adaptive immune responses are absent or impaired, such
asMtb/HIV co-infection, it would be desirable to not only boost their numbers and differentia-
tion capacity but also to induce IFN-γ secretion.
The development, maturation and maintenance of NK cells, CD8+ memory T cells and
most DN T cells relies on IL-15 and IL-2 [10–15]. The activity of these two cytokines is medi-
ated through trans-presentation, a mechanism by which the cytokine is presented to the cyto-
kine receptor complex beta and common γ chains in the context of cell-bound high-affinity
alpha (α) chains of the cytokine receptor [16, 17]. Both IL-2/anti-IL-2 and IL-15/IL-15RαFc
complexes have been shown to boost NK cell and memory CD8+ T cell numbers in mice and
to enhance their cytolytic capacity against viral-infected and cancer cells [16, 18–20]. Short-
term exposure of naïve mice with IL-2 complexes containing the anti-IL-2 mAb clone S4B6
has also been shown to enhance resistance and immunity against subsequent Listeria monocy-
togenes infection [21]. Additionally, IL-2 complexes containing the anti-IL-2 mAb clone JES6-
1A12 have been studied for their beneficial role in Treg expansion and activation in models of
autoimmunity, infection and cancer [22]. However, whether IL-2/anti-IL-2 cytokine complex-
mediated cell expansion can be harnessed as an effective measure to boost immunity against
active TB, or to prevent TB reactivation after HIV co-infection, is not known.
A critical limitation for studies onMtb/HIV co-infection is the lack of appropriate animal
models. Although several mouse and non-human primate models for TB have been developed
[23], these models are largely unsuitable to study HIV co-infection due to HIV’s restriction to
human cells. Simian immunodeficiency virus (SIV) infections in macaques mimic human HIV
infection, but for numerous reasons including ethical, financial and logistical ones this model
has substantial limitations. Similarly, the use of immunocompromised mice engrafted with
human hematopoietic progenitor cells (‘humanized mice’) [24] or infections of conventional
mice with ‘EcoHIV’, a modified HIV strain which infects mice [25], have only limited potential
as reliable, affordable and tractable HIV/Mtb co-infection animal models.
Our group has previously developed a murine TB ear dermis infection model that reflects
several aspects of human TB [26, 27]. In this model,Mtb only spreads to the spleen and lung in
mice lacking inducible nitric oxide synthase (iNOS) and these mice also develop human-like
lung granulomas [26]. In contrast, fully immunocompetent mice containMtb within the drain-
ing lymph node (LN) of the ear. We hypothesized that the transition from containment to sys-
temic spread depending on the immunological status of the host should allow reactivation of
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latent TB in this model through depletion of CD4+ T cells. Recently it was proposed that TB
has characteristic features of lymphatic diseases with a pulmonary portal and that pulmonary
pathology primarily servesMtb transmission [28]. In this context, using a latent lymphaticMtb
infection model presents an opportunity to studyMtb reactivation from a lymphocentric per-
spective. The present study examines a modified version of the murine ear dermisMtb infec-
tion model in conjunction with IL-2/anti-IL-2 complex treatment as a model for host-directed
immunotherapy to specifically boost and activate NK cells and CD8+ memory T cells during
progression to active TB as a consequence of CD4+ T cell deficiency.
Results
Depletion of CD4+ T cells reactivates chronic lymphaticMtb infection
To study progression from LTBI to active TB as a consequence of CD4+ T cell deficiency, as it
occurs in HIV co-infection, we first adapted the murine ear dermisMtb infection model [26,
27]. To this end, WT B6 mice were infected with 1 × 104 MtbH37Rv in the ear dermis and
thereafter treated weekly with either anti-CD4 monoclonal antibody (mAb) (GK1.5) or PBS
(Fig 1A). Twenty eight days post-infection (p.i), the bacterial burden in ear-draining LNs,
spleen and lung was assessed. PBS-treated animals almost exclusively containedMtb within
the draining LNs of the infected ear (Fig 1C). In some animals few bacteria were detected in the
spleen but never in the lung (Fig 1C). In contrast, in recipients of anti-CD4 mAb,Mtb not only
multiplied significantly within the LNs but also quickly exited the ear-draining LNs and spread
to spleen and lung in all animals (Fig 1C). Given that CD4+ T cells were efficiently depleted in
spleen, lung and LN in anti-CD4 mAb-treated animals (Fig 1B), we reasoned that this model
resembles progression from LTBI to active TB in human HIV/Mtb co-infection.
Fig 1. Depletion of CD4+ T cells reactivates chronic lymphaticMtb infection.Naïve B6mice were
infected i.d. with 1×104MtbH37Rv. At weekly intervals, mice received intraperitoneally (i.p.) a mAb against
mouse CD4 (GK1.5) or PBS (A). On day 28 p.i mice were sacrificed and ear-draining LNs, spleen and lung
were assessed for numbers of CD4+ T cells by FACS (B) and numbers of viable bacteria (C). Results are
presented as pooled data means ± SEM from one representative experiment (n = 4 mice per group). Statistical
analyses: Mann-WhitneyU-test per organ; significant differences are indicated by asterisks: ** p<0.01;
*** p<0.001.
doi:10.1371/journal.pone.0158849.g001
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Non-CD4 immune cells can be expanded in WT and CD4-deficient mice
Next we assessed whether non-CD4 lymphocyte subsets that have been implicated in early
control ofMtb [9], can be targeted with IL-2/anti-IL-2 complexes to compensate for the loss of
CD4+ T cells [20, 22]. To this end, naïve WT mice and CD4-depleted mice were treated with
IL-2/anti-IL-2 complexes or PBS andMtb-unrelated memory CD8+ T cells, NK cells and DN T
cells were enumerated (Fig 2A). In line with published data, the IL-2/anti-IL-2 complex con-
taining the anti-IL-2 mAb clone S4B6 but not the mAb clone JES6-5H4 for seven consecutive
Fig 2. Non-CD4 immune cells can be numerically expanded by treatment with IL-2/anti-IL-2
complexes. Naïve B6 mice (A, D) and anti-CD4-treated B6 mice (C, E) were treated i.p. with IL-2/anti-IL-2
complexes on seven consecutive days (A). One day after the last administration, mice were sacrificed and
numbers of CD3+CD8+, CD3+CD8+CD44+, CD3+CD8+CD44+, CD3+CD4−CD8− (DN) and CD3−NK1.1+ cells
in spleen (B, D, E) and lung (C) were assessed by FACS. Results are presented as pooled data means ±
SEM from two pooled independent experiments (n = 8 mice per group). Statistical analyses: One-way
ANOVA followed by Bonferroni multiple comparison test for non-parametric samples; significant differences
are indicated by asterisks: ** p<0.01; *** p<0.001; n.s. not significant.
doi:10.1371/journal.pone.0158849.g002
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days [22] caused a significant (>30 fold) expansion of CD8+ T cells, DN T cells and NK cells in
spleen, lung and LNs of naïve B6 mice (Fig 2B and 2C and data not shown). Within the CD8+
T cell compartment, IL-2/anti-IL-2-complex-treatment only expanded CD44+ but not CD44−
cells, indicating its selective beneficial effect on memory CD8+ T cells (Fig 2D). Moreover,
when B6 mice were additionally treated with anti-CD4 mAb prior to IL-2/anti-IL-2 complex,
the numerical expansion of memory CD8+ T cells, DN T cells and NK cells was even more dra-
matic (Fig 2E). Collectively, these results demonstrate that non-CD4 immune cell populations,
which contribute to early protection against TB [9], can be significantly expanded using IL-2/
anti-IL-2 complex in both WT and CD4-deficient mice.
Numerical expansion of non-CD4 immune cells fails to reverse TB
reactivation
In order to assess the impact of IL-2/anti-IL-2 complex-mediated expansion of non-CD4
immune cell populations in the murine ear dermis infection model, we combined the anti-
CD4-mediated reactivation ofMtb (Fig 1) with the expansion of non-CD4 immune cell popu-
lations (Fig 2). To this end, B6 mice were i.d. infected with 1 × 104 MtbH37Rv. Subsequently
two groups of mice were treated weekly with anti-CD4 mAb and one of these groups addition-
ally with IL2/anti-IL-2 complexes for seven consecutive days (Fig 3A). Recipients of anti-CD4
mAb only showed a progressive increase in bacterial numbers in LNs, spleen and lung over
time (Fig 3B–3D). Additional IL-2/anti-IL-2 complex treatment did not decrease numbers of
viable bacteria in LNs, spleen or lung (Fig 3B–3D). These data indicate that the sole expansion
of non-CD4 T cell populations is insufficient to restrict bacterial growth after reactivation of
LTBI.
Additionally, we performed a comprehensive cytokine and lung histology analysis over
time. Although cells expanded as expected (Fig 3E), IL2/anti-IL-2 treatment increased lung
pathology over time (Fig 3G). Furthermore, although the IL-2/anti-IL-2 treatment appeared to
reduce the upregulation of pro-inflammatory cytokines only within the first 28 days, an obvi-
ous and consistent shift within the cytokine profile was not observed long-term (Fig 3F). Taken
together these results indicate that IL-2/anti-IL-2-mediated expansion of non-CD4 lymphocyte
populations fails to prevent reactivation of LTBI in this model. The overall exacerbation of bac-
terial burden and lung pathology over time even indicates that significant detrimental adverse
events were induced by these treatments.
Shorter IL-2/anti-IL-2 treatment reduces immune pathology but not
bacterial burden
Although initial studies described a maximum cell expansion after six to seven administrations
of IL-2/anti-IL-2 complex [22], it was later found that such prolonged exposure to IL-2/anti-
IL-2 complexes can lead to T cell anergy in mice [21]. In these latter studies only formulations
with three but not five IL-2/anti-IL2 administrations protected mice from subsequent Listeria
monocytogenes and vaccinia virus infection [21]. To explore whether the failure of IL-2/anti-
IL-2 treatment to reverse lymphaticMtb reactivation in our model was due to T cell anergy, we
repeated the experiment described in Fig 3 with three instead of seven consecutive administra-
tions of IL-2/anti-IL-2 complex (Fig 4A).
Consistent with our previous observations, mice treated with anti-CD4 mAb displayed ele-
vated numbers ofMtb in LNs over time and progressively increasing numbers were detected
in spleen and lung (Fig 4B–4D). However, no reduction ofMtb numbers was observed when
mice were additionally treated with three doses of IL-2/anti-IL-2 complex (Fig 4B–4D). In
contrast to the longer IL-2/anti-IL-2 treatment, three doses significantly reduced abundance
AMouse Model for Reactivation of Latent Tuberculosis
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Fig 3. Expansion of non-CD4 immune cell populations fails to reverse reactivation of lymphatic LTBI.
Naïve B6 mice were infected i.d. with 1×104Mtb H37Rv. In weekly intervals mice received a depleting mAb
against mouse CD4 (GK1.5) or PBS i.p. One group of mice received IL-2/anti-IL-2 complexes i.p. on seven
consecutive days (A). On days 14, 28, 50 and 125 p.i. mice were sacrificed and ear draining LNs, spleen and
lung were assessed for numbers of viable bacteria (B–D) and numbers of CD3+CD4+, CD3+CD8+CD44+ and
CD3−NK1.1+ cells (E). Serum concentrations of cytokines (F) and lung pathology (G) were determined.
A Mouse Model for Reactivation of Latent Tuberculosis
PLOS ONE | DOI:10.1371/journal.pone.0158849 July 8, 2016 6 / 13
Results are presented as pooled data means ± SEM (B–D, G), individual data points (E), fold upregulation
relative to untreated controls (F) and representative images (G) from three pooled independent experiments
(n = 7–10 mice per group).
doi:10.1371/journal.pone.0158849.g003
Fig 4. T cell anergy does not explain failure to reverseMtb reactivation.Naïve B6 mice were infected i.d.
with 1×104Mtb H37Rv. In weekly intervals, mice received a depleting mAb against mouse CD4 (GK1.5) or
PBS i.p. One group of mice received IL-2/anti-IL-2 complexes i.p. on three consecutive days (A). On days 14,
28, 50 and 125 p.i., mice were sacrificed and ear-draining LNs, spleen and lung were assessed for numbers
of viableMtb (B–D). Additionally, serum cytokine concentrations (E) and lung pathology (F) were determined.
Results are presented as pooled data means ± SEM (B–D, F), fold upregulation relative to untreated controls
(e) and representative images (f) from two pooled independent experiments (n = 7–10 mice per group).
doi:10.1371/journal.pone.0158849.g004
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of inflammatory cytokines, lung pathology and general inflammation at later time points (Fig
4E and 4F). Although severity of lung pathology was greatly reduced by IL-2/anti-IL-2 com-
plex treatment,Mtb numbers in the lung were almost indistinguishable between anti-CD4
treated animals and anti-CD4 + IL-2/anti-IL-2-treated mice at day 140 p.i. These results indi-
cate that despite the failure of IL-2/anti-IL-2 complex treatment to prevent TB reactivation,
lung pathology was ameliorated by this treatment regimen. Hence further investigations into
the effects of IL-2/anti-IL-2 complex-mediated expansion of non-CD4 immune cells are
warranted.
Discussion
Here we describe a tractable mouse model to study latent lymphaticMtb infection, the progres-
sion to active TB after loss of CD4+ T cells and the impact of preventive expansion of non-CD4
lymphocytes by host-directed therapy. More specifically, we show that i.d. infection of B6 mice
withMtb resulted in LTBI restricted to ear-draining LNs. Treatment of latently infected mice
with anti-CD4 mAb caused TB reactivation and systemic spread ofMtb to spleen and lung,
mimicking the rapid progression from LTBI to TB in HIV+ individuals. Additionally, we report
that prophylactic host-directed therapy with IL-2/anti-IL-2 complexes to expand non-CD4
lymphocytes participating in protection against TB, fails to prevent TB reactivation in this
model. Although our results indicate limited potential of IL-2/anti-IL-2-mediated cell expan-
sion as adjunctive host-directed therapy inMtb/HIV co-infected individuals, the mouse model
described can be further exploited to study other aspects ofMtb reactivation and other treat-
ment regimens.
During the development of ART, recombinant IL-2 has been trialed as adjunctive AIDS
treatment by boosting CD4+ T cell numbers during ART. Indeed these approaches caused sub-
stantial and sustained increases in CD4+ T cell numbers yet; no clinically significant benefits of
IL-2 treatment over ART alone were observed [29–31]. IL-2 treatment has been more success-
fully used for treatment of persistent co-infections with drug-resistant mycobacteria in HIV+
individuals [32]. These studies aimed at numerical expansion of CD4+ T cell numbers to ame-
liorate infections with various opportunistic bacterial and parasitic pathogens in AIDS patients.
Given the better understanding of the role of non-CD4+ immune cells in early control of severe
bacterial infections, includingMtb and non-typhoidal Salmonella [9, 33, 34], we assessed bene-
ficial effects of boosting these cell types with IL-2/anti-IL-2 complexes. The apparent failure of
this approach in our newly established mouse model of progression from LTBI to active TB
could be due to the following non-mutually exclusive explanations: (i) transient expansion of
non-CD4 cell populations after IL-2/anti-IL-2 treatment; (ii) requirement of prophylactic
rather than preventive expansion of cell populations; (iii) activation of a pro-inflammatory
cytokine ‘storm’ that supports rather than limits initialMtb replication; and (iv) toxic side
effects of high doses of IL-2, such as vascular leakage syndrome [35], promotingMtb spread. It
is also unclear whether the IL-2/anti-IL-2 complexes remained stable and how much free IL-2
was administered. This obstacle could be overcome by using a stable chimeric protein of IL-2
and the anti-IL-2 clone S4B6 [36]. The hyper inflammatory response caused by IL-2/anti-IL-2
treatment in our model could also resemble aspects of the immune reconstitution inflamma-
tory syndrome (IRIS) that is frequently seen inMtb-infected AIDS patients on ART after
recovery of the immune system begins [37]. Furthermore, in vivo administration of anti-CD4
mAb likely also affects otherMtb-containing CD4+ cell types such as dendritic cells and macro-
phages. Depletion of these cell types may also impact the containment of LTBI in our model
and may mask any beneficial effects of IL-2/anti-IL-2 treatment. All of these issues require fur-
ther investigations and more refined models.
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IL-2 complexes have been used successfully in several other models. For example, Kanimura
and colleagues have trialed IL-2/anti-IL-2 complex treatment in a mouse model of B16 mela-
noma [38], and Tomala and colleagues in a mouse model of BCL1 leukemia [39] as cancer
immunotherapy. In these models, IL-2/anti-IL-2 complexes administered early after tumor
inoculation significantly increased the survival rate of mice [35]. Similarly, in a mouse model
of gamma-herpesvirus infection, IL-2 complex-mediated expansion of CD8+ T and NK cell
populations significantly reduced viral load in a perforin- and granzyme-dependent, IFN-γ-
independent manner [40]. To our knowledge, no data are available yet on any clinical use of
IL-2/anti-IL-2 complexes in humans.
IL-15/IL-15Rα-Fc complexes have been shown to significantly expand populations of mem-
ory CD8+ T cells, NK cells and DN T cells. In contrast to IL-2, IL-15 operates as a membrane-
bound complex in conjunction with the IL-15Rα-chain. This process, termed trans-presenta-
tion, allows more direct and more fine-tuned delivery of the cytokine signal to the recipient cell
[35], a relevant feature for clinical application. Additionally, IL-15/IL-15Rα-Fc complexes do
not induce Treg cells, as some IL-2/anti-IL-2 complexes do, and could therefore have more
potent effects. Whether IL-15/IL-15Rα-Fc complexes would perform better than IL-2/anti-IL-
2 complexes in our model ofMtb reactivation remains to be investigated.
In summary, our results provide a tractable and reproducible mouse model to study the
dynamics of progression from lymphatic LTBI to active TB following the loss of CD4+ T cells.
Furthermore, our findings suggest only limited potential of IL-2/anti-IL-2 complexes as
adjunctive therapy ofMtb/HIV co-infection. Finally, these results underpin the importance of
appropriate models to mimicMtb/HIV co-infection which allow broad-scale testing of host
directed therapies.
Materials and Methods
Ethics Statement
All experiments were conducted in accordance with requirements of and approval by the State
Office for Health and Social Services (Landesamt für Gesundheit und Soziales), Berlin, Ger-
many (G0031/13, T 0087/13).
Mice
C57BL/6 mice were purchased from Charles River, Sulzfeld, Germany and maintained in the
animal facilities of the Max Planck Institute for Infection Biology, Berlin, Germany. For
infection experiments, all mice were sex- and age-matched, and kept in-house in a biosafety
level 3 facility under specific pathogen free (SPF) conditions. Mice were sacrificed by cervical
dislocation.
Bacteria
MtbH37Rv was grown in Middlebrook 7H9 broth (BD Biosciences) supplemented with 0.2%
glycerol, 0.05% Tween 80 and 10% ADC enrichment (BD Biosciences) Mid-logarithmic cul-
tures were harvested, washed in PBS and stored at –80°C.
Infections and enumeration of bacteria
For i.d. infections, mice were anesthetized via i.p. injections of Rompun (5 mg/kg; Bayer) and
ketamin (50 mg/kg) and were subsequently infected with 1×104 cfuMtbH37Rv in the ear der-
mis in a volume of 50 μl. At designated time points, serial dilutions of tissue homogenates were
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plated onto Middlebrook 7H11 agar supplemented with 10% OADC Enrichment (BD Biosci-
ences) and ampicillin (25 μg/ml). Cfu were determined after 3–4 weeks incubation at 37°C.
mAb-mediated depletion of CD4+ T cells and assessment of depletion
CD4+ T cells were depleted from B6 mice by weekly i.p. injections of 200 μg mAb against CD4
(clone GK1.5). mAb were produced in-house from hybridoma cell lines.
IL-2/anti-IL-2 complex-mediated cell expansion
IL-2/anti-IL-2 complexes were prepared as previously described [22, 41]. Briefly, 1.5 μg of
recombinant mouse IL-2 (eBiosciences) and 10 μg of anti-IL-2 mAb (clone S4B6, produced in
house) were mixed, incubated at 37°C for 30 min, and administered i.p. in a volume of 200 μl
for up to seven consecutive days.
Isolation of lung leukocytes
Lungs were perfused with PBS, extracted, mechanically disrupted and digested via incubation
for 30 min with RPMI 1640 medium supplemented with glutamine, Na-pyruvate, 2-ME, peni-
cillin, streptomycin, 10% heat-inactivated FCS, collagenase D (Roche) and collagenase type
VIII (Sigma-Aldrich). Subsequently, red blood cell depleted, single-cell suspensions were pre-
pared as described elsewhere.
Flow cytometry
To assess expression of surface antigens, viable, red blood cell-depleted single splenocytes were
stained with mAb (all from BD Pharmingen) against CD4 (GK1.5), CD8α (53–6.7), CD3 (145-
2C11), CD44 (1M7) and NK1.1 (PK136) as described elsewhere. After washing the cells, sam-
ples were analyzed using a FACSCantoII or LSRII analyzers (BD Biosciences, CA). Propidium
iodide (2 μg/ ml) was added to exclude dead cells.
Histology
Lung lobes were collected aseptically, fixed overnight with 4% w/v paraformaldehyde and
embedded in paraffin. Two-μm tissues sections were stained with Giemsa or TB Flour accord-
ing to standard protocols as described elsewhere [42].
Multiplex
Blood for serum analysis was taken post mortem from the aorta abdominalis and collected in
serum separator tubes (BD), left for 30 min at room temperature, followed by centrifugation at
12,000 × g for 3 min. Sera were stored at –20°C until analysis. Measurements were performed
using a multiplex bead-based immunoassay kits (Bio-Rad) according to manufacturer’s
instructions. Samples were acquired on a Bio-Rad instrument.
Data and statistical analysis
Flow cytometry data was analyzed using FlowJo software (Treestar, CA) and statistical analysis
was performed using GraphPad Prism Version 5.04, GraphPad software, San Diego, CA as
indicated in individual figure legends.
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